PVR and neoplasm: As mentioned above, TIGIT functions particularly strongly as a ligand for PVR and is highly expressed in tumor-infiltrating lymphocytes in many cancers, including endometrial, breast, renal cell, non-small cell lung, and colon cancer (53).